Skip to Content
Merck
CN
  • Detection of pathological alpha-synuclein aggregates in human iPSC-derived neurons and tissue.

Detection of pathological alpha-synuclein aggregates in human iPSC-derived neurons and tissue.

STAR protocols (2021-03-19)
Iva Stojkovska, Joseph R Mazzulli
ABSTRACT

The accumulation of proteins into insoluble aggregates is a common feature of several neurodegenerative diseases. Aggregated α-synuclein is a major component of Lewy bodies that pathologically define Parkinson's disease (PD). Here, we present methods for the detection of pathogenic conformations of α-synuclein in induced pluripotent stem cell (iPSC) patient-derived neuron models and brain tissue. These methods can be applied to studies of PD pathogenesis and the discovery of novel therapeutics that restore physiological α-synuclein. For complete details on the use and execution of this protocol, please refer to Cuddy et al. (2019) and Zunke et al. (2018).

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Sodium orthovanadate, 99.98% trace metals basis
Sigma-Aldrich
Sodium dodecyl sulfate, ReagentPlus®, ≥98.5% (GC)
Sigma-Aldrich
Thioflavine S, practical grade
Sigma-Aldrich
HEPES, BioPerformance Certified, ≥99.5% (titration), suitable for cell culture
Sigma-Aldrich
Phenylmethanesulfonyl fluoride, ≥99.0% (T)
Sigma-Aldrich
Ethylenediaminetetraacetic acid disodium salt dihydrate, BioUltra, 98.5-101.5%
Sigma-Aldrich
Trizma® base, Primary Standard and Buffer, ≥99.9% (titration), crystalline
Sigma-Aldrich
Magnesium chloride hexahydrate, ACS reagent, 99.0-102.0%
Sigma-Aldrich
Sodium fluoride, ACS reagent, ≥99%